![]() Financial Daily from THE HINDU group of publications Sunday, May 15, 2005 |
|
|
|
|
|
Corporate
-
Alliances & Joint Ventures Win Medicare-Leo Pharma duo may expand to critical care segment P.T. Jyothi Datta
Mumbai , May 14 AFTER bringing in a range of skin-related products to treat psoriasis, Win Medicare Pvt Ltd expects to expand the scope of its deal with Denmark-based Leo Pharma to the critical care segment as well. But this will be only post-2006, after the range of products to treat psoriasis (a chronic skin condition) have been commercialised in India, said Mr Surjit S. Aurora, Vice-President with Win Medicare. "We will look at the critical care segment at products such as heparin, an anticoagulant (used to prevent the formation of blood-clots)," he told Business Line. Only recently Win Medicare formalised its deal with Leo Pharma for psoriasis and other dermatological conditions. As part of this deal, the company expects to launch Daivonex in the Indian market by September. Other similar products too are slated for the domestic market, including a reputed psoriasis product Daivobet, to be launched in November. Old therapies used to deal with psoriasis contain steroids and have side-effects. Daivonex, he said contained no steroids and was safe for long-term use. Leo Pharma is a $800-million company and more than half that revenue comes from the sales of Daivonex and Daivobet. Win Medicare expects Daivonex to clock about Rs 2 crore in its first year after launch. The product expects to touch sales of Rs 10 crore in three years, Mr Aurora said. Subsequently, Win Medicare would also bring in an opthamologic gel, Fucithalmic, by April next year. Explaining its application, he said that the gel becomes a drop when applied to the eye. Win Medicare is part of the U.K. Modi Group. The company has a host of marketing alliances with several multinational companies, including Switzerland's Mundi Pharma, Germany's Merz Pharmaceuticals GmbH and IBSA of Switzerland, to name a few. Win Medicare clocked revenues of Rs 120 crore for the year ended December 2004 and expects to end the current year at Rs 145 crore.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|